Tags

Type your tag names separated by a space and hit enter

Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.

Abstract

OBJECTIVES

We wanted to study the imbalance between antioxidant and oxidant generating systems resulting in oxidative stress (SOX) in end-stage renal disease (ESRD). We suggest that the plasma levels of Cu/Zn superoxide dismutase (Cu/Zn SOD) may be a new, sensitive marker of SOX in this population.

DESIGN AND METHODS

We measured the levels of Cu/Zn SOD and the traditional SOX markers-malondialdehyde (MDA), total peroxide, and autoantibodies against oxidized LDL (OxLDL-Ab) in the plasma of 132 uremic patients. In addition, circulating enzyme levels were analyzed in relation to the inflammation and presence of diabetes mellitus (DM).

RESULTS

Cu/Zn SOD levels were significantly higher in chronic renal failure (CRF) patients (P < 0.05), and in both dialyzed groups (both P < 0.001) than in controls, and were positively correlated with MDA, creatinine (both P < 0.001) and OxLDL-Ab (P < 0.01) in the whole uremic group.

CONCLUSIONS

The plasma levels of Cu/Zn SOD may be a simple, sensitive marker of SOX in ESRD, independent from DM and inflammation.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Nephrology and Clinical Transplantation, 14 Zurawia Street, 15-540 Bialystok, Poland. krystynapawlak@poczta.onet.pl

    ,

    Source

    Clinical biochemistry 38:8 2005 Aug pg 700-5

    MeSH

    Adult
    Autoantibodies
    Biomarkers
    Enzyme-Linked Immunosorbent Assay
    Female
    Humans
    Inflammation
    Kidney Failure, Chronic
    Lipoproteins, LDL
    Male
    Malondialdehyde
    Middle Aged
    Oxidative Stress
    Peritoneal Dialysis, Continuous Ambulatory
    Regression Analysis
    Renal Dialysis
    Reproducibility of Results
    Superoxide Dismutase

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    15963971

    Citation

    Pawlak, Krystyna, et al. "Cu/Zn Superoxide Dismutase Plasma Levels as a New Useful Clinical Biomarker of Oxidative Stress in Patients With End-stage Renal Disease." Clinical Biochemistry, vol. 38, no. 8, 2005, pp. 700-5.
    Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem. 2005;38(8):700-5.
    Pawlak, K., Pawlak, D., & Mysliwiec, M. (2005). Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clinical Biochemistry, 38(8), pp. 700-5.
    Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn Superoxide Dismutase Plasma Levels as a New Useful Clinical Biomarker of Oxidative Stress in Patients With End-stage Renal Disease. Clin Biochem. 2005;38(8):700-5. PubMed PMID: 15963971.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. AU - Pawlak,Krystyna, AU - Pawlak,Dariusz, AU - Mysliwiec,Michal, PY - 2005/01/20/received PY - 2005/02/12/revised PY - 2005/02/24/accepted PY - 2005/6/21/pubmed PY - 2005/11/8/medline PY - 2005/6/21/entrez SP - 700 EP - 5 JF - Clinical biochemistry JO - Clin. Biochem. VL - 38 IS - 8 N2 - OBJECTIVES: We wanted to study the imbalance between antioxidant and oxidant generating systems resulting in oxidative stress (SOX) in end-stage renal disease (ESRD). We suggest that the plasma levels of Cu/Zn superoxide dismutase (Cu/Zn SOD) may be a new, sensitive marker of SOX in this population. DESIGN AND METHODS: We measured the levels of Cu/Zn SOD and the traditional SOX markers-malondialdehyde (MDA), total peroxide, and autoantibodies against oxidized LDL (OxLDL-Ab) in the plasma of 132 uremic patients. In addition, circulating enzyme levels were analyzed in relation to the inflammation and presence of diabetes mellitus (DM). RESULTS: Cu/Zn SOD levels were significantly higher in chronic renal failure (CRF) patients (P < 0.05), and in both dialyzed groups (both P < 0.001) than in controls, and were positively correlated with MDA, creatinine (both P < 0.001) and OxLDL-Ab (P < 0.01) in the whole uremic group. CONCLUSIONS: The plasma levels of Cu/Zn SOD may be a simple, sensitive marker of SOX in ESRD, independent from DM and inflammation. SN - 0009-9120 UR - https://www.unboundmedicine.com/medline/citation/15963971/Cu/Zn_superoxide_dismutase_plasma_levels_as_a_new_useful_clinical_biomarker_of_oxidative_stress_in_patients_with_end_stage_renal_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(05)00064-0 DB - PRIME DP - Unbound Medicine ER -